Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chimeric Antigen Receptor-Modified T Cells Recognizing Ultralow-Density Tumor-Associated Antigens (CAR-T cells (ultralow-density TAA targeting))
- Target
- CAR-T cells (ultralow-density TAA targeting)
- Molecular classification
- Engineered Immunotherapy, Chimeric Antigen Receptor (CAR), T cell, Adoptive Cell Therapy
01
Overview
Chimeric antigen receptor (CAR)-modified T cells are genetically engineered immune cells designed to recognize and attack cancer cells by targeting specific tumor-associated antigens (TAAs) on their surface. These CAR-T cells are engineered to detect and respond to ultralow-density TAAs—antigens present at very low levels on tumor cell surfaces. These specialized CAR-Ts become activated, proliferate, secrete cytokines/interleukins/growth factors, and exert cytotoxic effects against the recognized cell population upon binding, even at ultralow densities.
- Other names
- Ultrasensitive CAR-T cellsEngineered T cells for low-antigen tumorsCAR-T cells targeting low-density TAAs
02
Mechanism of action
HLA-independent antigen recognition via engineered CAR; T cell activation and cytotoxicity upon binding ultralow-density tumor-associated antigens.
03
Biological functions
Antigen recognitionT cell activationCytokine secretionCytotoxicityTumor cell killingImmune response
04
Disease associations
CancerHematologic malignanciesSolid tumors
05
Safety considerations
On-target/off-tumor toxicity (autoimmunity)Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)Tumor lysis syndromeGraft-versus-host disease (GVHD) (in allogeneic settings)Insertional mutagenesis
06
Interacting drugs
Immunomodulatory agents (e.g., checkpoint inhibitors)
1 more in the full profile.
07
Biomarkers
Tumor-associated antigen (TAA) expression levelsCAR-T cell persistenceCytokine release syndrome (CRS) markersImmune effector cell-associated neurotoxicity syndrome (ICANS) markers
Beyond the preview
Go deeper on Chimeric Antigen Receptor-Modified T Cells Recognizing Ultralow-Density Tumor-Associated Antigens (CAR-T cells (ultralow-density TAA targeting)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chimeric Antigen Receptor-Modified T Cells Recognizing Ultralow-Density Tumor-Associated Antigens (CAR-T cells (ultralow-density TAA targeting)).